

NET SALES AS OF JUNE 30, 2018

Longjumeau, Tuesday, July 24, 2018

PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of June 30, 2018.

The PCAS Group had generated consolidated net sales of €100.4 million as of June 30, 2018, representing a decrease of 8.9% compared to the same period of the previous financial year (-7.0% at a constant exchange rate).

<i>In millions of euros</i>	2018	2017	Growth in %	2018 At a constant exchange rate	Growth in %
Net sales as of June 30	100,4	110,2	-8,9%	102,5	-7,0%
<i>Pharmaceutical Synthesis</i>	<i>61,6</i>	<i>75,8</i>	<i>-18,6%</i>	<i>63,0</i>	<i>-16,9%</i>
<i>Fine Specialty Chemicals</i>	<i>38,7</i>	<i>34,4</i>	<i>12,4%</i>	<i>39,6</i>	<i>14,9%</i>

Pharmaceutical Synthesis

The Pharmaceutical Synthesis business generated €61.6 million, down 18.6% compared to 2017 (-16.9% at constant exchange rates), partly due to first half-year multi-stage productions and projects being put back, the sales of which should be achieved over the second part of the year.

Fine Specialty Chemicals

Net sales of Fine Specialty Chemicals totaled €38.7 million, up 12.4% on 2017 (+14.9% at constant exchange rates), with growth in both Performance Additives (Lubricants) and Advanced Specialty Chemicals for the micro-electronics part.

Outlook

In 2018, the Group's net sales are expected to show modest growth. However, the Group income may be noticeably affected if the current euro/USD exchange rate were to worsen.



NEXT FINANCIAL DISCLOSURE:

First half 2018 results, Wednesday, September 05, 2018

ABOUT PCAS

PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €218.3 million in 2017 and employs close to 1 100 people in six countries.

To find out more about PCAS, visit: www.pcas.com



PCA
LISTED
EURONEXT

PCAS

NewCap

Vincent Touraille / Eric Moissenot
PCAS

Tel. : +33 1 69 79 61 32
www.pcas.com

Emmanuel Huynh / Louis-Victor Delouvier
NewCap
Financial communication and Investor Relations

Tel. : +33 1 44 71 98 53
pcas@newcap.eu